Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Charles River And WuXi PharmaTech Count Down To Shareholder Votes On Proposed Merger, Research Analysts Predict Defeat

This article was originally published in PharmAsia News

Executive Summary

BEIJING - As Charles River Laboratories and WuXi PharmaTech count down toward crucial shareholder votes on Aug. 5 - on whether their proposed union should go forward or be shot down - the American and Chinese drug research outfits have issued a new call for ratification of the plan

You may also be interested in...

Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support For Deal

BEIJING - The heads of the Massachusetts-based Charles River Laboratories and the Shanghai-headquartered WuXi PharmaTech issued a joint appeal calling for shareholders to rally in support of the proposed union of the two contract research organizations during near-simultaneous votes four weeks from now

Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO

BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts